Dual GIP/GLP-1 agonists add GIP receptor activation, which: Amplifies insulin secretion beyond what GLP-1 alone achieves Increases insulin sensitivity in peripheral tissues Appears to shift adipocyte metabolism toward fat oxidation (mechanism still under investigation) May reduce the nausea signal that limits GLP-1 dose escalation (GIP has anti-emetic properties in animal models) The weight loss ceiling for tirzepatide is approximately 20% to 22% of baseline body weight at the 15 mg dose over 72 weeks (SURMOUNT-1 data)
This nutrient-rich blend is also packed with phytosterols, which are known to visibly improve skins elasticity
It mimics the natural fat-reducing action of HGH without the unwanted side effects on blood sugar or growth
Contraindications: Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
The pivotal clinical trials for semaglutide (SUSTAIN and STEP programs) did not specifically enroll or report outcomes for patients with Crohn's disease or ulcerative colitis, representing a significant knowledge gap in the literature
Meanwhile, the growth of TGIN highlights demand for textured hair-focused, inclusive brands that cater to diverse needs with plant-based formulations
